CAS 2160546-07-4

Formule : C17H18Cl2N6

InChI : InChI=1S/C17H18Cl2N6/c1-17(20)5-7-25(8-6-17)12-9-21-15-14(23-24-16(15)22-12)10-3-2-4-11(18)13(10)19/h2-4,9H,5-8,20H2,1H3,(H,22,23,24)

Code InChI : AMADCPJVPLUGQO-UHFFFAOYSA-N

SMILES : CC1(CCN(CC1)C2=NC3=NNC(=C3N=C2)C4=C(C(=CC=C4)Cl)Cl)N

IACS-13909

CAS : 2160546-07-4

IACS-13909

Formule : C₁₇H₁₈Cl₂N₆

Degré de pureté : ≥98%

Masse moléculaire : 377.27

Ref: 54-BUP03097

1-(3-(2,3-Dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-4-methylpiperidin-4-amine

CAS : 2160546-07-4

Degré de pureté : 98%

Ref: IN-DA01WTBP

IACS-13909

CAS : 2160546-07-4

1-(3-(2,3-Dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-4-methylpiperidin-4-amine

Formule : C₁₇H₁₈Cl₂N₆

Degré de pureté : 97%

Masse moléculaire : 377.27

Ref: IN-DG01387008

IACS-13909

CAS : 2160546-07-4

IACS-13909 (BBP-398), a specific and potent allosteric inhibitor of SHP2, that suppresses signaling through the MAPK pathway.

Formule : C₁₇H₁₈Cl₂N₆

Degré de pureté : 98.8%

Couleur et forme : Solid

Masse moléculaire : 377.27

Ref: TM-T9196

IACS-13909

CAS : 2160546-07-4

IACS-13909 is a drug that binds to EGFR and inhibits the kinase activity of EGFR. It is being developed as an anti-cancer drug for the treatment of cancer, with a particular focus on cancers that are resistant to ibrutinib. IACS-13909 has shown potent anticancer activity in preclinical studies, with no adverse effects on healthy cells. IACS-13909 has been used in clinical trials for the treatment of cancer, with promising results.

Formule : C₁₇H₁₈Cl₂N₆

Degré de pureté : Min. 95%

Masse moléculaire : 377.3 g/mol

Ref: 3D-KLD54607